HIKARU NAKAJIMA, M.D.
Hematology & Oncology Physician in EAST STROUDSBURG, Pennsylvania. CMS National Plan and Provider Enumeration System profile including specialty classification, practice address, and Medicare prescribing data when reported.
What the federal data shows
HIKARU NAKAJIMA, M.D. reported a CMS MIPS final score of 95.6426/100 — above the 83.1 national average — and filed 2,441 Medicare Part D claims in 2023.
- 95.6426/100
- MIPS score · +13 vs avg
- 2K
- Part D claims, 2023
- 87%
- generic prescribing
- Likely
- board-certified (heuristic)
Every figure on this page comes straight from federal CMS records (NPPES, Medicare Part D, MIPS, Open Payments) — no proprietary rating or editorial opinion is applied.
HIKARU NAKAJIMA, M.D.'s MIPS score vs every scored U.S. clinician
CMS Merit-based Incentive Payment System (MIPS) final score, 2023 — the federal quality measure
96 Top 21% higher than 79% of 477,587 scored providers
Each bar is a band; taller bars hold more scored providers. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source CMS Merit-based Incentive Payment System (MIPS) · 2023
HIKARU NAKAJIMA, M.D. practices in an ABMS-board-eligible specialty and shows active CMS Medicare participation + MIPS quality reporting — signals consistent with board-certified status. For verified board certification, see CertificationMatters.org (the official ABMS public lookup).
What does the federal data show about HIKARU NAKAJIMA, M.D.?
High performer (top quartile)Primary specialty
Medicare Part D claims
MIPS final score
Specialty distribution in Pennsylvania
How Hematology & Oncology Physician compares to other specialties among Pennsylvania providers
Hematology & Oncology Physician share within Pennsylvania
Hematology & Oncology Physician is one of the more visible NUCC categories in Pennsylvania
Each bar reflects the share of in-state providers whose primary NUCC taxonomy matches the specialty. Long tail of ~690 NUCC codes folded into "Other" to keep the comparison legible.
Medicare quality performance — MIPS
HIKARU NAKAJIMA, M.D.'s 2023 MIPS final score plotted against the Hematology & Oncology Physician national average
- MIPS Final Score
- 95.6426/100
- vs 83.1 national avg · 2023 performance year
MIPS final score (Hematology & Oncology Physician) — 95.6426/100 vs national avg 83.1
Quality benchmarks
- National MIPS avg 2023 reporting year
- Quality dim CMS Quality category
- Specialty volume Hematology & Oncology Physician US NPIs
95.6426/100 MIPS final score — 12.5 pts above the 83.1 national average
Quality, Cost, Promoting Interoperability, and Improvement Activities composite score for the 2023 performance year. Specialty: Hematology & Oncology Physician. Quality dim: 80.5735.
The Merit-based Incentive Payment System (MIPS) scores providers 0–100 across four performance categories: Quality, Cost, Promoting Interoperability, and Improvement Activities, weighted under 42 CFR §414.1380. Reporting is voluntary for many small practices, so absence of a MIPS score is not a quality signal.
Board certification through an ABMS or AOA member board signals voluntary post-licensure examination plus continuous Maintenance of Certification cycles. Verify any individual provider's status through certificationmatters.org (ABMS) or osteopathic.org (AOA).
HIKARU NAKAJIMA, M.D. appears in the CMS NPPES registry as a Hematology & Oncology Physician provider holding M.D. credentials at 181 E BROWN ST, EAST STROUDSBURG, PA, 18301, with a listed phone of (570) 422-1700. NPI 1134306517 was issued on 01/28/2008. Because NPPES data is self-reported by the provider and refreshed monthly, the address, phone, and specialty reflect what NAKAJIMA most recently submitted to CMS rather than a vetted directory listing, which is why patients should always confirm the practice is still at this location before scheduling.
Medicare Part D records for calendar year 2023 show 2,441 prescription claims written by this provider, covering 600 Medicare beneficiaries and totaling roughly $4.8 million in drug spend, split 13% brand-name and 87% generic by claim count, with an opioid prescribing rate of 1.1%. These figures capture only Medicare Part D — commercial insurance, Medicaid, and cash-pay prescriptions are not included, and any drug-beneficiary cell under 11 is suppressed by CMS for patient privacy. On the CMS Merit-based Incentive Payment System, this provider earned a Final Score of 95.6426/100 for the 2023 performance year (Quality 80.5735), compared with the national average of 83.1.
Hematology & Oncology Physician is a mid-sized specialty nationwide, with 11,215 enrolled providers across 54 states and an average of 847 Part D claims per prescriber, so the context for interpreting these metrics differs meaningfully from a primary-care baseline. Important: PlainDoctor is a directory of publicly available government data, not medical advice, a malpractice database, or a quality rating. Inclusion here does not imply a recommendation, and absence of complaints or sanctions on this page does not mean none exist — always verify credentials through the NPPES NPI Registry, your state medical board, and the ABMS or AOA before making healthcare decisions.
Practice Address
Provider Details
| NPI | 1134306517 |
|---|---|
| Specialty | Hematology & Oncology Physician |
| Credentials | M.D. |
| Gender | Male |
| NPI Issued | 01/28/2008 |
Verify this provider's license
PlainDoctor pulls this profile from the CMS NPPES public registry. Confirm HIKARU NAKAJIMA, M.D.'s current license status, disciplinary history, and board certifications with the Pennsylvania State Board of Medicine in Pennsylvania before relying on this page for a clinical or care decision.
How we sourced this profile
CMS Quality Score (MIPS)
Merit-based Incentive Payment System (MIPS) scores from CMS, 2023 performance year.
Reporting: Alternative Payment Model
License & disciplinary context — Pennsylvania PA-BOM 2023 annual report
Aggregate state board data only — NOT a determination of any individual provider's status. The figures below describe statewide disciplinary activity across all ~45K Pennsylvania medical licensees in 2023 — they are NOT specific to HIKARU NAKAJIMA, M.D.. To verify HIKARU NAKAJIMA, M.D.'s current license status, search the PA-BOM public license lookup directly, or check the Federation of State Medical Boards (FSMB) verification service.
PA-BOM publishes annual disciplinary statistics as part of public-record reporting under each state's Administrative Procedure Act. See the full breakdown by action type and year on the Pennsylvania disciplinary trends page. Cross-checked against FSMB U.S. Medical Regulatory Trends.
Brand vs generic prescribing mix · Typical
13% brand-name claims vs 87% generic, on 2,441 2023 Medicare Part D claims.
The federal Medicare Part D Generic Dispensing Rate national benchmark sits near 90% generic / 10% brand for primary-care prescribers, per CMS Office of the Actuary 2024 estimates. Higher brand share is common in specialty prescribing where generic equivalents are not available.
Medicare Part D Prescribing Data
CMS Medicare Part D prescriber-level data for calendar year 2023.
Prescribing Breakdown
- 30-Day Fills
- 5,485
- Total Day Supply
- 159,380
- Brand vs Generic
- 13% brand / 87% generic
- Brand Drug Cost
- $4.4M
- Generic Drug Cost
- $385K
- Opioid Claims
- 27 (1.1% rate)
- Antibiotic Claims
- 28
Patient Demographics
- Average Patient Age
- 73.7 years
- Avg HCC Risk Score
- 1.61
- Gender Split
- 93% female / 8% male
- Age Distribution
- <65: 47, 65-74: 286, 75-84: 211, 85+: 56
Top Prescribed Drugs (Medicare Part D)
Top drugs by claim count for calendar year 2023. Based on Medicare Part D data only.
What HIKARU NAKAJIMA, M.D. prescribes most
Top Medicare Part D drugs by claim count, 2023
- Anastrozole
Anastrozole
1,307 claims
- Letrozole 150
Letrozole
150 claims
- Ibrance 132
Ibrance
132 claims
- Exemestane 87
Exemestane
87 claims
- Prednisone 76
Prednisone
76 claims
- Ondansetron Hcl 69
Ondansetron Hcl
69 claims
- Tamoxifen Citrate 59
Tamoxifen Citrate
59 claims
- Abiraterone Acetate 48
Abiraterone Acetate
48 claims
| Drug | Claims |
|---|---|
| Anastrozole | 1,307 |
| Letrozole | 150 |
| Ibrance Palbociclib | 132 |
| Exemestane | 87 |
| Prednisone | 76 |
| Ondansetron Hcl | 69 |
| Tamoxifen Citrate | 59 |
| Abiraterone Acetate | 48 |
| Acyclovir | 44 |
| Imbruvica Ibrutinib | 44 |
* Counts below 11 are suppressed by CMS for patient privacy. Generic names shown where available from CMS Part D data.
Hematology & Oncology Physician Overview
How HIKARU NAKAJIMA, M.D. fits within the Hematology & Oncology Physician landscape nationally.
HIKARU NAKAJIMA, M.D.'s 2,441 claims are above the specialty average of 847.
Nearby Hematology & Oncology Physician Providers in Pennsylvania
Other clinicians with the same primary specialty enrolled in Pennsylvania, drawn from the same CMS NPPES roster as NAKAJIMA.
Compare Hematology & Oncology Physician nationally: see state-by-state distribution →
Healthcare Guides
Learn more about finding, verifying, and understanding healthcare providers.
Explore Pennsylvania
Frequently Asked Questions
What is HIKARU NAKAJIMA, M.D.'s specialty? ▼
How much does HIKARU NAKAJIMA, M.D. prescribe under Medicare Part D? ▼
What is HIKARU NAKAJIMA, M.D.'s Medicare quality score? ▼
Where is HIKARU NAKAJIMA, M.D. located? ▼
What is HIKARU NAKAJIMA, M.D.'s NPI number? ▼
Does HIKARU NAKAJIMA, M.D. prescribe more brand-name or generic drugs? ▼
Does HIKARU NAKAJIMA, M.D. prescribe opioids? ▼
How many Hematology & Oncology Physician providers are there in the US? ▼
What drugs does HIKARU NAKAJIMA, M.D. prescribe most often? ▼
Does HIKARU NAKAJIMA, M.D. accept Medicare? ▼
How can I verify HIKARU NAKAJIMA, M.D.'s credentials? ▼
Data Sources
- Provider Directory
- CMS National Plan and Provider Enumeration System (NPPES), download.cms.gov/nppes, updated monthly. Contains NPI, specialty, credentials, and practice location.
- Specialty Classification
- NUCC Health Care Provider Taxonomy (nucc.org), the industry standard for classifying provider specialties in Medicare and Medicaid billing.
- Prescribing Data
- CMS Medicare Part D Prescriber Public Use File (2023). Includes claims, drug costs, beneficiaries, and opioid prescribing rates.
- Quality Performance
- CMS Merit-based Incentive Payment System (MIPS) — 2023 performance year.
- Limitations
- Provider data is self-reported to CMS. Prescribing data reflects Medicare Part D only and does not include commercial insurance, Medicaid, or cash prescriptions. Claims below 11 beneficiaries are suppressed by CMS for privacy.
See our complete data methodology for details on how we collect and process government data.
Data as of April 2026 (NPPES) / 2023 (Medicare Part D). Source: Centers for Medicare & Medicaid Services (CMS).
Disclaimer: Data from CMS NPPES and Medicare Part D. PlainDoctor does not rate or rank providers. Provider information is self-reported and may not be current. Always verify information directly with the provider. About · Methodology